IPEC e-newsletter - Excipients Insight June/July 2017 - 10-07-17

 

Inside this issue

     

Europe delays decision on EMA's new home

The decision on which country will host the European Medicines Agency (EMA) once the UK leaves the EU has been postponed by one month.

A verdict on the new location for the agency when it moves from London will now be made in November, after a meeting of the heads of state or government from the 27 states that will make up the EU after March 29, 2019. The EU's November meeting will also see a decision on the post-Brexit location of the European Banking Authority (EBA), which must also leave London.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has voiced its concern about the delay, whilst acknowledging the complexity of the Brexit negotiations, saying that "medicines constitute a special case in term of securing swift agreement on both sides."

"It is imperative for the safeguarding of public health that we ensure future alignment between the UK and EU regulatory regimes in order to maintain capacity, processes and timeframes for the introduction of new medicines for patients, EFPIA added.

Meanwhile, the Association of the British Pharmaceutical Industry (ABPI) executive director of research, medicine and innovation, Dr Virginia Acha, said: "It will be critical to avoid divergence and duplication of regulatory regimes, so that patient safety is not put at risk."

At least 21 countries are thought to have proposed cities to host the EMA – including Copenhagen, Barcelona, Lisbon and Dublin – and any others that are interested have until July 31 to submit a formal offer.

 

 

 

Copyright © 2005 - 2017 IPEC Europe - International Pharmaceutical Excipients Council